Prognosis of Dental Implants in Patients With Primary Sjögren's Syndrome

Dental Implant Clinical Trial

Official title:

Prognosis of Dental Implants in Patients With Primary Sjögren's Syndrome. A Prospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04960605
• Other study ID #: 1036_2015
• Status: Completed
• Phase: N/A
• Start date: January 1, 2015
• Est. completion date: October 27, 2023

Study information

• Verified date: November 2023
• Source: University of Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Sjögren's Syndrome (PSS) is a chronic autoimmune inflammatory disease primarily involving the salivary and lacrimal glands. Few data exist regarding survival and success rate of dental implants in patients with PSS. Although a previous study suggest lower success rate for dental implants we hypothesize that dental implants have similar survival and success rate in PSS as healthy controls. The purpose of the present study was to evaluate the long-term survival and success rate of dental implants in patients with PSS compared to the healthy controls.

Description:

Sjögren's syndrome (SS) affects about 5% of population worldwide. Patients with Primary Sjögren's Syndrome (PSS) have dry mouth, oral mucosal problems, increased dental decay and problems wearing dentures. A retrospective case series indicated that implant survival rate may be reduced among SS patients. Furthermore, there is lack of scientific evidence to support success or failure of dental implants in SS-patients. The null hypothesis is that the outcome of implant treatment after 5 years is similar in patients with primary Sjögren's Syndrome (pSS) compared to matched controls. The participants with PSS fulfilled the Copenhagen Criteria and/or the US-EU criteria for PSS, miss at least one tooth and have sufficient bone volume for a single implant insertion without bone augmentation. Recruitment of PSS patients was done via own existing databases on PSS patients as well as repeated national announcements in the Danish Dental Journal. We included 24 consecutive participants with PSS. For each participant with PSS (test group), an age, gender, and tooth-type matched healthy participant (control group) was enrolled (n=24). The surgical part of the implant treatment was carried out by two experienced maxillofacial surgeons. Straumann implants (Straumann Bone level Roxolid®) with a hydrophilic sandblasted, acid etched implant surface (SLActive) was used for all participants. If more than one implant was placed, the study implant was determined according to a randomization scheme. The inserted implants were allowed to heal for 3 months before the prosthetic part, which was carried out by two experienced prostodontists. The same prosthetic material and method was applied for all participants. The participants were recalled for baseline (2 months after prosthetic loading) and 1, 3 and 5 years examination, where the biological (marginal bone level, inflammation etc.), technical (fractures, loosening's etc.), esthetic (Copenhagen Index score) and patient-reported (Oral Health Impact Profile questionnaire/OHIP-49) assessments were performed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: October 27, 2023
• Est. primary completion date: October 27, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• - Age 20-70 years
• Indication of tooth replacement with implant-supported fixed dentures
• The test group should be without any potentially associated disease
• pSS must be diagnosed according to the American-European Consensus Group criteria

(Vitali et al., 2002):

1. The presence of any 4 of the following 6 items, as long as either item IV (Histopathology) or VI (Serology) is positive

2. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V, VI) The items:

I. Ocular symptoms: a positive response to at least one of the following questions:

1. Have you had daily, persistent, troublesome dry eyes for more than 3 months?

2. Do you have a recurrent sensation of sand or gravel in the eyes?

3. Do you use tear substitutes more than 3 times a day?

II. Oral symptoms: a positive response to at least one of the following questions:

1. Have you had a daily feeling of dry mouth for more than 3 months?

2. Have you had recurrently or persistently swollen salivary glands as an adult?

3. Do you frequently drink liquids to aid in swallowing dry food? III. Ocular signs --that is, objective evidence of ocular involvement defined as a positive

result for at least one of the following two tests:

1. Schirmer's I test, performed without anaesthesia (<5 mm in 5 minutes)

2. Rose bengal score or other ocular dye score (>4 according to van Bijsterveld's scoring system) IV. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a focus score >1, defined as a number of lymphocytic foci (which are adjacent to normal-appearing mucous acini and contain more than 50 lymphocytes) per 4 mm2 of glandular tissue V. Salivary gland involvement: objective evidence of salivary gland involvement defined by

a positive result for at least one of the following diagnostic tests:

1. Unstimulated whole salivary flow (<1.5 ml in 15 minutes)

2. Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary or destructive pattern), without evidence of obstruction in the major ducts

3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer

VI. Autoantibodies: presence in the serum of the following autoantibodies:

1. Antibodies to Ro(SSA) or La(SSB) antigens, or both

• The control group should match the test group according to the age, sex and treatment

region and fulfill the following:

• Normal salivary flow: unstimulated > 1.5 ml in 15 min, stimulated > 3.5 ml in 5 min
• No ocular or oral symptoms
• Submission of written informed consent form

Exclusion Criteria:

• Persons with:

1. secundary Sjögren Syndrom (sSS)

2. severe systemic disease including severe bleeding disorder and/or conditions which put the patient at risk and/or prohibit compliance as stated by Hwang and

Wang, 2006; and Hwang and Wang, 2007):

3. previous or present bisphosphonate, Denosumab or anti-angiogenetic chemotherapeutic drugs

4. poor bone quality according to Lekholm U & Zarb GA (1985) or diagnosed osteoporosis

5. Heavy smokers, eqv. to 20+ cigarettes/day

6. Noncompliance

Related Conditions & MeSH terms

• Dental Implant
• Primary Sjögren Syndrome
• Sjogren's Syndrome
• Syndrome

Intervention

Procedure:
• Dental implants
Treatment of the toothless regions with dental implants

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
University of Copenhagen	Gigtforeningen, ITI Foundation, Rigshospitalet, Denmark

References & Publications (4)

Hosseini M, Gotfredsen K. A feasible, aesthetic quality evaluation of implant-supported single crowns: an analysis of validity and reliability. Clin Oral Implants Res. 2012 Apr;23(4):453-8. doi: 10.1111/j.1600-0501.2011.02162.x. Epub 2011 Mar 28. — View Citation

Isidor F, Brondum K, Hansen HJ, Jensen J, Sindet-Pedersen S. Outcome of treatment with implant-retained dental prostheses in patients with Sjogren syndrome. Int J Oral Maxillofac Implants. 1999 Sep-Oct;14(5):736-43. — View Citation

Pedersen AM, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome. BMC Clin Pathol. 2005 Mar 1;5(1):4. doi: 10.1186/1472-6890-5-4. — View Citation

Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, Schiodt M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P, Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, McNamara N, Sack K, Shirlaw P, — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with Sjögren syndrom	number of participants in the test group	Five years
Primary	Number of patients without Sjögren syndrom	number of participants in the control group	Five years
Primary	Number of implants in each group	number of implants in patients with or without Sjögren syndrom	Five years
Primary	Marginal bone loss	Marginal bone level change over the time in millimeter: radiological examinations and measurements of the marginal bone at implants mesially and distally (millimeter) and the change of the marginal bone level between different observation	Five years
Primary	Frequency of implant sites with biological complications	Frequency of implant sites with sign of inflammatory reactions with or without marginal bone loss (periimplantitis or peri-implant mucositis). The number of implant sites with bleeding on probing, suppuration or fistula will be registered and described.	5 year
Primary	Sialometry	measurement of stimulated or unstimulated saliva flow, ml/min for all participants and statistical comparison between the participants in both groups.	5 year
Primary	Technical outcome	The frequency of prosthetic complications such as fracture or loosening of implant-supported crowns at all implant sites in all participants and comparison between to groups	5 years
Primary	Aesthetic outcome by Copenhagen Index Scores	Aesthetic parameters: Symmetry/harmony, Crown morphology, Crown color match, mucosal discoloration, Papilla Index score mesially and distally Score 1, 2, 3 and 4 (socre 1 for the most optimal and socre 4 for unacceptable aesthetic outcome)	5 year
Primary	Patient-reported outcome	Oral Health Impact on the Quality of Life (OHIP-49 questionnaire) Response scale from 0 (never experienced problem) to 4 (problem experienced very often).	5 years
Secondary	Decayed, Missing, Filled Tooth index (DMFT)	Caries experience by calculation of total number of tooth with Decayed, Missing or Filled tooth. Less scores indicating better dental condition. Both groups will be compared and the relation to sialometry will be analyzed.	5 years
Secondary	Modified Plaque Index	The Oral hygiene of the patients will be measured by recording the amount of the plaque on the implants and all natural teeth using the following scale: (score 1 to 4) Score 1: no visible plaque; Score 2: small amount of hardly visible plaque; Score 3: moderate amount of plaque; Score 4: abundant amount of plaque The difference in plaque index and the relation to the biological complication will be statistically analyzed in both group of participants.	5 years
Secondary	Modified Mucosal Index scores	The sign of inflammatory reactions around the implants will be measured by using the following scores: (score 1 to 4) Score 1: normal appearance of gingiva/mucosa; Score 2: slight redness or hyperplasia; Score 3: moderate inflammation with marked redness and hyperplasia and easily bleeding by probing; Score 4: Severe inflammation with severe redness and hyperplasia and spontaneous bleeding The difference in mucosal index and the relation to the plaque index will be statistically analyzed in both group of participants.	5 years